European medical research still ignoring women

February 05, 2007

Despite the European Union's commitment to gender equality, women are still underrepresented on the committees that sanction research while the impact of gender differences continues to be ignored in clinical trials, suggests a study in the Journal of Medical Ethics.

The authors assessed the composition and procedures of two major research ethics committees in European member states, including Ireland, Germany, Sweden, Austria and The Netherlands in 2003.

Before research can be carried out, it must be submitted to a research ethics committee to ensure that it complies with good ethical practice and is of sufficient quality.

The authors found a great deal of variation in the regulations governing the committees they assessed. Some were governed locally; others nationally.

As to the gender make-up of the committees, all of them had informal rules requiring the inclusion of at least some women, and took sex into account when recruiting new members.

But few had any formal rules.

And while every committee had formal requirements to ensure that certain types of expertise were represented, these did not include experts on sex and gender issues.

All committees had protocols for research involving drugs and women of childbearing age, to ensure that unborn children are protected from harm.

But none was required to ensure that sufficient numbers of both sexes were included in any piece of research, or that any potential benefits or harms did not unfairly affect either sex.

Only Sweden had clear national guidelines on these issues.

The authors conclude that despite the existence of a European Union policy on gender equality in health research funded by the EU, the research ethics committees "paid only limited attention" to it.

They also point out that gender equality has also been left out of the recent EU clinical trials directive, which was intended to harmonise practice across member states.

More education of the importance of gender differences in health is needed, say the authors to ensure that research is properly designed and evaluated for the benefit of patients and doctors
-end-


BMJ Specialty Journals

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.